WEYBRIDGE, England--(BUSINESS WIRE)--Idis, a leading specialist in the creation of managed access programmes for medicines for healthcare professionals and their patients with unmet medical needs, today named Jeff Thomis as the Company’s Chairman.
“I look forward to working with the Board at Idis to ensure we drive the growth of the organisation whilst maintaining our patient focused approach to developing and delivering the best managed access programmes.”
The appointment is effective immediately. In his new role, Jeff will work with the Board and the leadership team in delivering the company’s future growth plans and meeting its goal of becoming the global authority in access to medicines worldwide.
Jeff spent 15 years at Quintiles, the global clinical research organisation, including as President of Global Clinical Development Services and Chairman of the American Management Board. He brings a wealth of pharma and clinical research strategic leadership experience at board level. His expertise lies in helping to grow international businesses in a rapidly changing healthcare environment.
“I am delighted to be appointed Chairman of Idis. As specialists in the field, Idis is strongly placed to deliver highly effective solutions to our customers who include pharmaceutical and biotech companies, healthcare professionals and patients,” said Jeff Thomis. Commenting on his new role, Thomis added, “I look forward to working with the Board at Idis to ensure we drive the growth of the organisation whilst maintaining our patient focused approach to developing and delivering the best managed access programmes.”
- ENDS -
Idis has 25 years experience of partnering with pharmaceutical and biotechnology companies to create regulatory-compliant, ethical access to medicines for healthcare professionals and their patients with unmet medical needs. Since 1987, Idis has developed and managed access to thousands of medicines from every therapeutic category, impacting the lives of hundreds of thousands of patients in countries around the world.
Idis leverages decades of experience, regulatory insight, and a thorough understanding of local and global requirements to create access to medicines at every stage of a product’s lifecycle from pre-approval to market exit, and in times of unexpected production shortages.
The company’s European headquarters are located in Weybridge, United Kingdom, and North American headquarters are located in Princeton, NJ.
For more information about Idis please visit www.idispharma.com
About Jeff Thomis
Jeff spent 15 years at Quintiles, the global clinical research organisation during which time he was President of the European Clinical Development Services and then President of Global Clinical Development Services. Most recently he was Chairman of the American Management Board, reporting to Dennis Gillings, Chairman and CEO of Quintiles. Jeff has grown businesses across Europe, International and US markets in a number of roles, establishing Quintiles Clinical Development Services as the leader in the field of Global Clinical Research Organisations.
In his early career, Jeff spent 20 years with Bristol Myers Squibb, playing a major part in the development and registration (NDA, sNDA) of eight commercially successful cardiovascular and infectious disease products. He also has a significant depth of knowledge within the cardiovascular therapy area; he has also managed a large patient access programme with the HIV treatment didanosine (Videx) and served on WHO Committee on access to HIV drugs.
Jeff qualified as a pharmacist from University of Leuven, Belgium and three years later achieved his Ph.D. in Pharmaceutical Sciences, again from the University of Leuven.